TAK-925 / Danavorexton

Eugeroic

Wakefulness in narcolepsy/anesthesia recovery positioning

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Small molecule
Primary mechanism: Orexin 2 receptor agonism
Primary market use: Narcolepsy/wakefulness

Pharmacology

Molecular weight (Da): ~450
Oral bioavailability: Unknown
Half-life: ~4 h; not fully established
Route tags: Route-dependent / verify
Evidence level: Clinical
Clinical status: Investigational
Value-for-money score: 5 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Acute receptor pharmacology

Sources

https://clinicaltrials.gov/